Management of advanced prostate cancer in the Asia‐Pacific region: Summary of the Asia‐Pacific Advanced Prostate Cancer Consensus Conference 2023-Reference-Cited by-同舟云学术

Management of advanced prostate cancer in the Asia‐Pacific region: Summary of the Asia‐Pacific Advanced Prostate Cancer Consensus Conference 2023

Published:2024-04-16 Issue: Volume: Page:
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clncl Oncology

Author:

Chiong Edmund¹,Murphy Declan G.²,Buchan Nicholas³⁴,Chen Kenneth⁵,Chen Sarah S.⁶,Chua Melvin L. K.⁷^ORCID,Hamid Agus Rizal⁸,Kanesvaran Ravindran⁹,Khochikar Makarand¹⁰,Letran Jason¹¹,Lojanapiwat Bannakij¹²,Mallik Indranil¹³,Ng Chee Fai¹⁴,Ong Teng Aik¹⁵,Poon Darren M. C.¹⁶,Pu Yeong‐Shiau¹⁷,Saad Marniza¹⁸,Schubach Kathryn⁴¹⁹,Takahara Kiyoshi²⁰,Tey Jeremy²¹^ORCID,Thang Sue‐Ping²²,Toh Poh Choo¹,Türkeri Levent²³,Vinh Nguyễn Tuấn²⁴,Williams Scott⁴²⁵,Ye Dingwei²⁶, ,Davis Ian D.²⁷^ORCID

Affiliation:

1. Department of Urology, National University Hospital, and Department of Surgery National University of Singapore Singapore Singapore

2. Division of Cancer Surgery Peter MacCallum Cancer Centre Melbourne Australia

3. Department of Urology Christchurch Public Hospital Christchurch New Zealand

4. Monash University, Melbourne, Australia, Eastern Health Melbourne Australia

5. Department of Urology Singapore General Hospital Singapore Singapore

6. Department of Nursing Tan Tock Seng Hospital Singapore Singapore

7. Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology National Cancer Centre Singapore Singapore Singapore

8. Department of Urology Faculty of Medicine Universitas Indonesia – CiptoMangunkusumo Hospital Jakarta Indonesia

9. Division of Medical Oncology National Cancer Centre Singapore Singapore Singapore

10. Department of Urology/Uro‐oncology Ushakal Abhinav Institute of Medical Sciences Sangli India

11. Department of Urology Chinese General Hospital and Medical Center Manila Philippines

12. Department of Surgery Chiang Mai University Chiang Mai Thailand

13. Department of Radiation Oncology Tata Medical Center Kolkata India

14. SH Ho Urology Centre The Chinese University of Hong Kong Hong Kong China

15. Department of Surgery Universiti Malaya Kuala Lumpur Malaysia

16. Department of Clinical Oncology The Chinese University of Hong Kong Hong Kong China

17. Department of Urology National Taiwan University College of Medicine and Hospital Taipei Taiwan

18. Department of Clinical Oncology, Faculty of Medicine Universiti Malaya Kuala Lumpur Malaysia

19. Australian and New Zealand Urology Nurses (ANZUNS) Melbourne Australia

20. Department of Urology Fujita Health University Toyoake Japan

21. Department of Radiation Oncology National University Cancer Institute Singapore Singapore Singapore

22. Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital Singapore Singapore

23. Department of Urology Altunizade Hospital, Acibadem M.A. Aydinlar University Istanbul Turkey

24. Department of Urology Binh Dan Hospital Ho Chi Minh City Vietnam

25. Department of Radiation Oncology Peter MacCallum Cancer Centre Melbourne Australia

26. Department of Urology Fudan University Shanghai Cancer Center Shanghai China

27. Lifehouse Camperdown Australia

Abstract

AbstractAimThe aim of the third Asia‐Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2023) was to discuss the application in the Asia‐Pacific (APAC) region of consensus statements from the 4th Advanced Prostate Cancer Consensus Conference (APCCC 2022).MethodsThe one‐day meeting in July 2023 brought together 27 experts from 14 APAC countries. The meeting covered five topics: (1) Intermediate‐ and high‐risk and locally advanced prostate cancer; (2) Management of newly diagnosed metastatic hormone‐sensitive prostate cancer; (3) Management of non‐metastatic castration‐resistant prostate cancer; (4) Homologous recombination repair mutation testing; (5) Management of metastatic castration‐resistant prostate cancer. Pre‐ and post‐symposium polling gathered APAC‐specific responses to APCCC consensus questions and insights on current practices and challenges in the APAC region.ResultsAPAC APCCC highlights APAC‐specific considerations in an evolving landscape of diagnostic technologies and treatment innovations for advanced prostate cancer. While new technologies are available in the region, cost and reimbursement continue to influence practice significantly. Individual patient considerations, including the impact of chemophobia on Asian patients, also influence decision‐making.ConclusionThe use of next‐generation imaging, genetic testing, and new treatment combinations is increasing the complexity and duration of prostate cancer management. Familiarity with new diagnostic and treatment options is growing in the APAC region. Insights highlight the continued importance of a multidisciplinary approach that includes nuclear medicine, genetic counseling, and quality‐of‐life expertise. The APAC APCCC meeting provides an important opportunity to share practice and identify APAC‐specific issues and considerations in areas of low evidence where clinical experience is growing.

Funder

Bayer

Astellas Pharma Canada

AstraZeneca

Pfizer

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.14064

Reference49 articles.

1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

2. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

3. Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

4. Managing advanced prostate cancer in the Asia Pacific region: “Real‐world” application of Advanced Prostate Cancer Consensus Conference 2019 statements

5. Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis